



American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & Exposition

December 14, 2022

FORT MYERS, Fla., Dec. 14, 2022 – [American Oncology Network, LLC](#) (AON) is pleased to announce that seven research studies co-authored by AON physicians were presented at the [American Society of Hematology \(ASH\) Annual Meeting & Exposition](#), held December 10-13 in New Orleans, Louisiana.

More than 5,000 scientific abstracts are submitted each year, and those accepted for oral and poster presentations have gone through an extensive peer review process. The final abstracts featured at the ASH annual meeting represent important, novel research in the field.



Ruemu E. Birhiray, MD
Medical Oncologist
Hematology Oncology
of Indiana




Ralph V. Boccia, MD, FACP
Medical Oncologist
Center for Cancer
& Blood Disorders



Arvind Chaudhry, MD, PhD
Medical Oncologist
Summit Cancer Centers



George Negrea, MD
Medical Oncologist
Low Country Cancer Care



Victor M. Priego, MD
Medical Oncologist
Center for Cancer &
Blood Disorders

The following AON physician investigators presented their research results during poster discussions and presentations at the ASH Annual Meeting & Exposition:

- [Dr. Ruemu E. Birhiray](#) of Hematology Oncology of Indiana presented and served as co-author of a study titled *In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years* (Abstract # 3255).
- [Dr. Ralph V. Boccia](#) of The Center for Cancer and Blood Disorders served as co-author of several studies titled *Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)* (Abstract # 1598), *Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia* (Abstract # 2185) and *Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)* (Abstract # 4271).
- [Dr. Arvind Chaudhry](#) of Summit Cancer Centers served as co-author of several studies titled *Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies* (Abstract # 1587) and *Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies* (Abstract # 4176).
- [Dr. Victor M. Priego](#) of The Center for Cancer and Blood Disorders served as co-author of a study titled *A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies* (Abstract # 2893).

In addition, [Dr. George Negrea](#) of Low Country Cancer Care served as co-author of a study titled *Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusion* to be published on the [ASH abstracts site](#).

"Being selected to present your research is an esteemed honor," said AON Research Committee Chairman [Dr. Ralph Boccia](#), Board-certified medical oncologist and hematologist at The Center for Cancer and Blood Disorders. "With high numbers of submitted materials being considered, the abstracts selected offer premier research findings that are deemed noteworthy and important to cancer care. Congratulations to these AON physicians for sharing their studies with the medical community, and we thank them for their dedication to improving patient care."

"The field of cancer research is constantly evolving with new and revolutionary findings that transform patient care and treatment," said AON CEO [Todd Schonherz](#). "It is critical for physicians, and other members of the care team, to remain dedicated to continuing their education so that patients are receiving the right care at the right time. To have five AON physicians contributing their knowledge and expertise illustrates their commitment to advancing the industry forward by leading innovative research projects that elevate cancer care across the entire healthcare landscape."

###

About American Oncology Network, LLC

The [American Oncology Network, LLC](#) (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 107 physicians and 89 nurse practitioners and physician assistants practicing across 18 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients' experiences are at the very pinnacle of cancer care today. Learn more at [AONcology.com](#).

Contact for more information:

Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com